[
  {
    "ts": null,
    "headline": "Why The Narrative Around Arvinas Is Shifting After Recent Pipeline And Partnership Changes",
    "summary": "Arvinas has seen its consensus analyst price target drop from $18.44 to $17.44 in the latest review. This change reflects new uncertainty after the company and Pfizer announced plans to seek a third-party partner for vepdegestrant, which has raised concerns about commercialization timing and strategy. Stay tuned to discover how you can follow ongoing updates as Arvinas’ story continues to unfold. What Wall Street Has Been Saying Analyst commentary on Arvinas reflects a divided view following...",
    "url": "https://finnhub.io/api/news?id=84e3c00c7f45e1ae8d8141c88a6313ac05f4c524b135c2f1238012eabf4169d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758983103,
      "headline": "Why The Narrative Around Arvinas Is Shifting After Recent Pipeline And Partnership Changes",
      "id": 136904133,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Arvinas has seen its consensus analyst price target drop from $18.44 to $17.44 in the latest review. This change reflects new uncertainty after the company and Pfizer announced plans to seek a third-party partner for vepdegestrant, which has raised concerns about commercialization timing and strategy. Stay tuned to discover how you can follow ongoing updates as Arvinas’ story continues to unfold. What Wall Street Has Been Saying Analyst commentary on Arvinas reflects a divided view following...",
      "url": "https://finnhub.io/api/news?id=84e3c00c7f45e1ae8d8141c88a6313ac05f4c524b135c2f1238012eabf4169d4"
    }
  },
  {
    "ts": null,
    "headline": "Metsera (MTSR): Rethinking Valuation After a Quiet 49% Rally",
    "summary": "Metsera (NasdaqGS:MTSR) has recently caught the eye of many investors, even without a headline-grabbing event. Sometimes a stock’s movement in the absence of big news can be just as telling, sparking questions about whether investors are re-evaluating the company’s future or if a new trend is quietly taking shape. This situation often leads to a closer look at what might be driving interest behind the scenes, beyond just the headlines. Over the past month, Metsera shares have climbed almost...",
    "url": "https://finnhub.io/api/news?id=4fa4b63db2a30d0d15e4dd17246ea34d8aa950852db97e806b15565fa5677888",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758980793,
      "headline": "Metsera (MTSR): Rethinking Valuation After a Quiet 49% Rally",
      "id": 136904482,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Metsera (NasdaqGS:MTSR) has recently caught the eye of many investors, even without a headline-grabbing event. Sometimes a stock’s movement in the absence of big news can be just as telling, sparking questions about whether investors are re-evaluating the company’s future or if a new trend is quietly taking shape. This situation often leads to a closer look at what might be driving interest behind the scenes, beyond just the headlines. Over the past month, Metsera shares have climbed almost...",
      "url": "https://finnhub.io/api/news?id=4fa4b63db2a30d0d15e4dd17246ea34d8aa950852db97e806b15565fa5677888"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?",
    "summary": "The company continues to improve its pipeline.",
    "url": "https://finnhub.io/api/news?id=f13306511ee1924abbeb1cf1e3ccd85cee85a68c507c9052ed812aefb83a7075",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758975300,
      "headline": "Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?",
      "id": 136904036,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The company continues to improve its pipeline.",
      "url": "https://finnhub.io/api/news?id=f13306511ee1924abbeb1cf1e3ccd85cee85a68c507c9052ed812aefb83a7075"
    }
  },
  {
    "ts": null,
    "headline": "3 Magnificent Stocks Under $100 to Buy Right Now",
    "summary": "You won't need a huge amount of cash to invest in these great pharma stocks.",
    "url": "https://finnhub.io/api/news?id=8fe1dc209442d35802c79b27de1a4e740ba48d31a42c785f07f5c12ee57b23cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758969900,
      "headline": "3 Magnificent Stocks Under $100 to Buy Right Now",
      "id": 136904135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "You won't need a huge amount of cash to invest in these great pharma stocks.",
      "url": "https://finnhub.io/api/news?id=8fe1dc209442d35802c79b27de1a4e740ba48d31a42c785f07f5c12ee57b23cd"
    }
  }
]